Work, from our lab and others, has established that the beneficial, anti-cancer function of the p16INK4a tumor suppressor mechanism also untowardly contributes to mammalian aging. In this model, the age-associated expression of p16INK4a compromises organismal fitness by limiting the regeneration and repair of certain self-renewing compartments. In support of this hypothesis, recent data from our lab and collaborators has shown that p16INK4a-deficient animals demonstrate a resistance to certain aging phenotypes in pancreatic -cells, neural stem cells and hematopoietic stem cells, while transgenic animals expressing excess p16INK4a demonstrate an accelerated functional decline with aging in these compartments. Additional support for this model has come from recent human genome-wide and candidate association studies which have linked single nucleotide polymorphisms near the CDKN2a locus, which encodes p16INK4a, to human age-associated conditions such as frailty, type 2 diabetes and atherosclerotic disease (myocardial infarction, ischemic stroke and abdominal aortic aneurysm). In the renewal of this proposal, we seek to extend these prior observations to further enhance our understanding of how p16INK4a influences mammalian aging.
In specific aim I, we propose to further define the role of p16INK4a in pancreatic -cell aging using a novel p16INK4a-conditional allele generated in our lab.
In specific aim II, we will further study the role of p16INK4a in a murine model of atherosclerosis using germline and conditional p16INK4a-deficient mice.
In specific aims III and IV, we will focus on the role of p16INK4a in lymphocyte aging.
In aim III, we will characterize T- and B-cell number and function in mice harboring somatic inactivation of p16INK4a in these tissues.
In aim I V, we will study the expression of p16INK4a in human T-cells with aging and after exposure to age-promoting stimuli such as cytotoxic chemotherapy. Through these approaches, we will further delineate the contribution of p16INK4a to age-associated phenotypes such as type 2 diabetes, atherosclerosis and immune dysfunction in humans in mice.
Some aspects of aging result from a decline in the ability of tissues to repair and regenerate. This decline in tissue regenerative capacity is in part caused, in some cell types, by activation of the cell's intrinsic anti-cancer machinery. Human genetic studies have suggested this process is of particular importance in aging-related diseases such as atherosclerosis and type 2 diabetes. In this work, we use experimental systems in humans and mice to investigate the role of anti-cancer mechanisms in aging.
|Deng, Jiehui; Wang, Eric S; Jenkins, Russell W et al. (2018) CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8:216-233|
|Diekman, Brian O; Sessions, Garrett A; Collins, John A et al. (2018) Expression of p16INK4a is a biomarker of chondrocyte aging but does not cause osteoarthritis. Aging Cell :e12771|
|He, Shenghui; Sharpless, Norman E (2017) Senescence in Health and Disease. Cell 169:1000-1011|
|He, Shenghui; Roberts, Patrick J; Sorrentino, Jessica A et al. (2017) Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med 9:|
|Dumond, J B; Collins, J W; Cottrell, M L et al. (2017) p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects. CPT Pharmacometrics Syst Pharmacol 6:120-127|
|Palacio, L; Krishnan, V; Le, N L O et al. (2017) Sustained p16INK4a expression is required to prevent IR-induced tumorigenesis in mice. Oncogene 36:1309-1314|
|Souroullas, George P; Fedoriw, Yuri; Staudt, Louis M et al. (2017) Lkb1 deletion in murine B lymphocytes promotes cell death and cancer. Exp Hematol 51:63-70.e1|
|Dumond, J B; Chen, J; Cottrell, M et al. (2017) Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers. CPT Pharmacometrics Syst Pharmacol 6:128-135|
|Demaria, Marco; O'Leary, Monique N; Chang, Jianhui et al. (2017) Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse. Cancer Discov 7:165-176|
|Maas, Brian M; Francis, Owen; Mollan, Katie R et al. (2016) Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection. PLoS One 11:e0168709|
Showing the most recent 10 out of 47 publications